- Home
- ITRG vs BBOT Comparison
ITRG vs BBOT Comparison
Compare ITRG & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITRG | BBOT |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | Canada | United States |
| Employees | N/A | 106 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.9M | 605.6M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | ITRG | BBOT |
|---|---|---|
| Price | $2.21 | $8.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $5.13 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 3.6M | 510.7K |
| Earning Date | 05-11-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $67.34 | N/A |
| Revenue Next Year | $25.89 | N/A |
| P/E Ratio | $45.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.43 | $7.00 |
| 52 Week High | $4.87 | $14.87 |
Technical Indicators
Market Signals| Indicator | ITRG | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 39.78 | 52.92 |
| Support Level | N/A | $8.02 |
| Resistance Level | $2.86 | $9.50 |
| Average True Range (ATR) | 0.14 | 0.58 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 13.00 | 47.47 |
Price Performance
Historical ComparisonAbout ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About BBOT BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.